Indications -- Lupus/Nephritis Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- Lupus/Nephritis

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: keokalani'nui who wrote (7)	4/17/2001 3:22:52 PM
From: keokalani'nui	Read Replies (1) of 95

Genelabs. Aslera. From Pharmaceutical Approvals Monthly. Genelabs Aslera lupus NDA will be reviewed by the Arthritis Advisory Committee April 19, with likely discussion of lupus trial endpoints. The firm’s two pivotal studies contain data on a range of endpoints, including bone mineral density information requested by FDA. Marketing partner Watson is expecting a mid-year launch for the lupus therapy. fdcreports.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next